Zymeworks(US:ZYME) Globenewswire·2025-12-02 21:05Core Insights - Zymeworks Inc. is actively participating in significant upcoming conferences, including the ASCO Gastrointestinal Cancers Symposium and the J.P. Morgan Annual Healthcare Conference, showcasing its innovative biotherapeutics and clinical trials [1][5]. Conference Participation - Zymeworks will present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma, at the ASCO GI Symposium on January 9, 2026 [2]. - The company will also highlight the late-breaking HERIZON-GEA-01 presentation, focusing on Ziihera® in HER2-driven gastrointestinal cancers, at the same symposium [1][3]. Presentation Details - The ZW251 presentation will be part of a multicenter study involving participants with hepatocellular carcinoma, scheduled for January 9, 2026, from 11:30 am to 1:00 pm PT [2]. - The HERIZON-GEA-01 study results will be presented on January 8, 2026, during the Oral Abstract Session A, focusing on advanced HER2-positive gastroesophageal adenocarcinoma [3]. Company Overview - Zymeworks is a biotechnology company focused on developing a diverse pipeline of multifunctional biotherapeutics aimed at improving treatment for difficult diseases, including cancer [6]. - The company utilizes its proprietary Azymetric™ technology to engineer Ziihera®, a HER2-targeted bispecific antibody, and has established partnerships for its commercialization [6].